60186-15-4 Usage
Uses
Used in Organic Synthesis:
2,4-Difluoro-5-nitropyridine is used as a key ingredient in the production of various pharmaceutical drugs and agrichemical products. Its unique chemical structure makes it a valuable component in the synthesis of complex organic molecules.
Used in Medicinal Chemistry:
2,4-Difluoro-5-nitropyridine is used as a building block in drug discovery processes. Its presence in the molecular structure of potential drug candidates can contribute to the development of new therapeutic agents with improved pharmacological properties.
Used in Pharmaceutical Industry:
2,4-Difluoro-5-nitropyridine is used as a starting material for the synthesis of various pharmaceutical drugs. Its incorporation into drug molecules can enhance their efficacy, selectivity, and safety profiles, leading to the development of novel therapeutic options for patients.
Used in Agrichemical Industry:
2,4-Difluoro-5-nitropyridine is used as a precursor in the production of agrichemical products, such as pesticides and herbicides. Its chemical properties can be harnessed to create more effective and environmentally friendly agricultural chemicals.
Check Digit Verification of cas no
The CAS Registry Mumber 60186-15-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,0,1,8 and 6 respectively; the second part has 2 digits, 1 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 60186-15:
(7*6)+(6*0)+(5*1)+(4*8)+(3*6)+(2*1)+(1*5)=104
104 % 10 = 4
So 60186-15-4 is a valid CAS Registry Number.
60186-15-4Relevant academic research and scientific papers
FUSED RING HETEROARYL COMPOUNDS AS RIPK1 INHIBITORS
-
Paragraph 0208, (2021/02/12)
The invention provides novel substituted heterocyclic compounds represented by Formula I, or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided c
PYRIMIDINE CARBOXAMIDES AS GSK-3 INHIBITORS
-
Page/Page column 16, (2018/06/12)
The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3.
GSK-3 INHIBITORS
-
Page/Page column 94; 95, (2018/06/12)
The disclosure generally relates to compounds of formula (I), including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3.
GSK-3 INHIBITORS
-
Page/Page column 106, (2015/05/26)
The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3.
